Intercell Hopes To Pack Pipeline With Iomai

forbes.com     May 13, 2008            

Intercell is planning to acquire the needle-free immunization developer, Iomai, for $189.0 million, or $6.60 a share, in hopes of becoming the international traveler's best friend with a new portfolio of vaccines for voyagers. Shares of Iomai (nasdaq: )'s deal values Iomai's stock at a 126.0%... [read full story]                    


*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies